Ergomed
Ergomed is recorded as a service provider in 12 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 12 of 12 trials · Latest update first
Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients with Alagille Syndrome or Progressive Familial Intrahepatic Cholestasis in the European Union (LEAP-EU)
Sponsor Mirum Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
- Not reported
Multicentre, open-label, phase 1/2 study of LB-208, selective antagonist of the serotonin 5-hydroxytryptamine receptor 1B (HTR1B), in adults with relapse or refractory (r/r) acute myeloid leukaemia (AML) and r/r higher-risk (HR) myelodysplastic syndrome (MDS)
Sponsor Aop Orphan Pharmaceuticals GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Phase 3, Single-Arm, Open-label, Pivotal Study to Evaluate the Efficacy and Safety of Ersodetug Compared to Baseline in Patients with Inadequately Controlled Hypoglycemia Due to Tumor-Associated Hyperinsulinism (Tumor HI)
Sponsor Rezolute Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2a, Open-label, Single-Arm Study Investigating Tolerability of IV/IM Administration of RetinolX (retinol palmitate) in Preterm Infants, and Measuring Serum Levels of Retinol, Retinol Palmitate and Retinol Binding Protein (RBP4) (PARELETO - Trial)
Sponsor Aspire Pharma Limited
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Phase I/II Multicenter, Open-Label Study of Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors
Sponsor Nouscom S.r.l.
- Start (EU)
- Latest update
- Estimated end
A Phase 1, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGN151 (anti-FRα antibody-drug conjugate) in Adult Patients with Recurrent Gynaecological Cancers
Sponsor AbbVie Deutschland GmbH & Co. KG
- Start (EU)
- Latest update
- Estimated end
A multicentre, prospective, open-label, uncontrolled Phase 3 study to assess the efficacy, safety and pharmacokinetics of Atenativ in patients with congenital antithrombin deficiency undergoing surgery or delivery
Sponsor Octapharma AG
- Start (EU)
- Latest update
- Estimated end
A Phase I/II, Open-Label, Multi-Center Study of ALE.C04 (anti-Claudin-1 Antibody) as a Single Agent and in Combination with Pembrolizumab (anti-PD-1 antibody) in Adult Patients with Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma
Sponsor Alentis Therapeutics AG
- Start (EU)
- Latest update
- Estimated end
A Phase 3 open-label, controlled, randomised, multi-centre trial comparing imlifidase and standard-of-care with standard-of-care alone in the treatment of severe anti-GBM antibody disease (Goodpasture disease)
Sponsor Hansa Biopharma AB
- Start (EU)
- Latest update
- Estimated end
Multicenter, open-label, phase 2 study of carboplatin plus mirvetuximab soravtansine followed by mirvetuximab soravtansine continuation in folate receptor-alpha positive, recurrent platinum sensitive, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancer following 1 prior line of platinum-based chemotherapy
Sponsor AbbVie Deutschland GmbH & Co. KG
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy And Safety Of Adjunctive Recombinant Human Plasma Gelsolin With Standard of Care for Moderate-to-Severe ARDS Due to Pneumonia or Other Infections
Sponsor Bioaegis Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A 6-Month Phase 3, Multicenter, Prospective, Randomized, Double-Blind, Vehicle-Controlled Study, to Evaluate the Efficacy and Safety of Topically Applied Clascoterone (Cortexolone 17α-Propionate) Solution for the Treatment of Androgenetic Alopecia in Males, Followed by a 6-Month Single-Blind Treatment with Clascoterone or Vehicle BID Solution (SCALP 2)
Sponsor Cassiopea S.p.A.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Ergomed?
The 2026-10-09 snapshot links Ergomed to 12 distinct CTIS trials. Recorded services include Clinical monitoring, Regulatory services, Investigator recruitment, Project management, among 16 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Ergomed?
The most frequently recorded therapeutic areas are Endocrinology, Gastroenterology, Genetic and Congenital Disorders, Haematological Malignancies. Recorded phases include Phase 2, Phase 1, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Ergomed conducted?
The linked trials record locations in 17 countries, including Spain, Germany, France, Italy, Belgium. These are trial locations, not confirmed office locations or countries where Ergomed delivered services.
What can this page tell me about Ergomed's trial experience?
Browse 12 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 5 recorded name variants under Ergomed. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- ERGOMED Center for Data Management and Statistics GmbH
- Ergomed Clinical Research Inc.
- Ergomed Clinical Research Limited
- Ergomed Group Limited
- Ergomed PLC